Phase II Trial of Fulvestrant With Metronomic Capecitabine for Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Clinical Breast Cancer - United States
doi 10.1016/j.clbc.2013.09.003
Full Text
Open PDFAbstract
Available in full text
Date
February 1, 2014
Authors
Publisher
Elsevier BV